Pemetrexed 500 MG Injection [Axtle] — RxCUI 2699341
RxNorm drug concept · Semantic branded drug
RxCUI 2699341
Semantic branded drug · SBD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2699341
Official namePemetrexed 500 MG Injection [Axtle]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asAxtle 500 MG Injection
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)71 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Pemetrexed Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It treats non-squamous non-small cell lung cancer and malignant pleural mesothelioma. Depending on your situation, it may be given alone or with cisplatin, or with pembrolizumab an...
- It is given through an IV over about 10 minutes, usually once every 21 days. You also need daily folic acid, a vitamin B12 shot, and dexamethasone around each treatment. These help...
- How will I get it, and what else do I need to take?
- Tiredness, nausea and loss of appetite are common. Vomiting, mouth sores, constipation, diarrhea, rash and low blood counts can also happen, depending on what you take it with. You...
🕸️ Concept Web — How Pemetrexed 500 MG Injection [Axtle] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Pemetrexed 500 MG Injection [Axtle]
RxCUI 2699341 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Pemetrexed
68446IN
-
Pemetrexed
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Axtle
2699335BN
-
Axtle
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Pemetrexed Injection
1728071SCDF -
Pemetrexed Injectable Product
1161384SCDG -
Pemetrexed Injection [Axtle]
2699338SBDF -
Axtle Injectable Product
2699337SBDG -
Injection
1649574DF -
Injectable Product
1151126DFG
-
Pemetrexed Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Pemetrexed 500 MG Injection
1728072SCD -
Pemetrexed 500 MG
1728070SCDC -
Pemetrexed 500 MG [Axtle]
2699340SBDC
-
Pemetrexed 500 MG Injection
Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Pemetrexed 500 MG Injection
SCD · 1728072 -
Pemetrexed 500 MG
SCDC · 1728070 -
Pemetrexed Injection
SCDF · 1728071 -
Pemetrexed Injectable Product
SCDG · 1161384
Brand-Name Concepts
-
Pemetrexed 500 MG [Axtle]
SBDC · 2699340 -
Pemetrexed Injection [Axtle]
SBDF · 2699338 -
Axtle Injectable Product
SBDG · 2699337 -
Axtle
BN · 2699335
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 2699341 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 83831-0131-01 | 1 VIAL in 1 CARTON (83831-131-01) / 4 mL in 1 VIAL | AXTLE | Avyxa Pharma, LLC | 2025-01-01 |
| 83831-0132-01 | 1 VIAL in 1 CARTON (83831-132-01) / 20 mL in 1 VIAL | AXTLE | Avyxa Pharma, LLC | 2025-01-01 |
Observed labelers:
Avyxa Pharma, LLC (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J9292 | Inj, pemetrexed dipotassium | 2 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.